Imugene Limited (ASX:IMU)
0.0330
0.00 (0.00%)
Mar 28, 2025, 4:10 PM AEST
Imugene Revenue
Imugene had revenue of 1.26M AUD in the half year ending December 31, 2024, a decrease of -73.86%. This brings the company's revenue in the last twelve months to -1.84M, down -112.24% year-over-year. In the fiscal year ending June 30, 2024, Imugene had annual revenue of 4.97M, down -57.80%.
Revenue (ttm)
-1.84M
Revenue Growth
-112.24%
P/S Ratio
n/a
Revenue / Employee
-367.92K
Employees
5
Market Cap
246.36M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.97M | -6.81M | -57.80% |
Jun 30, 2023 | 11.78M | -1.19M | -9.19% |
Jun 30, 2022 | 12.97M | 5.74M | 79.35% |
Jun 30, 2021 | 7.23M | 3.10M | 74.94% |
Jun 30, 2020 | 4.13M | 6.56K | 0.16% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionImugene News
- 7 months ago - Imugene Ltd Azer-cel Trial Update Transcript - GuruFocus
- 1 year ago - Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort - GlobeNewsWire
- 1 year ago - Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 - GlobeNewsWire
- 1 year ago - Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts - GlobeNewsWire
- 1 year ago - Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium - Accesswire
- 1 year ago - NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments - PRNewsWire
- 3 years ago - City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors - Business Wire
- 3 years ago - Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer - GlobeNewsWire